1199809-30-7

Basic information

• Product Name: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine
• Synonyms: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine
• CAS NO: 1199809-30-7
• Molecular Formula: C13H18FN5O4
• Molecular Weight: 327.315
• Mol File: 1199809-30-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine(CAS DataBase Reference)
• NIST Chemistry Reference: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine(1199809-30-7)
• EPA Substance Registry System: (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine(1199809-30-7)

Safety Data

• Hazardous Substances Data: 1199809-30-7(Hazardous Substances Data)

Usage

General Description

(2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine is a chemical compound that is a modified form of the nucleoside guanosine. It contains a deoxyribose sugar molecule with a 6-O-ethyl substituent and a 2'-fluoro and 2'-methyl modification on the guanosine base. This modification gives the compound increased stability and resistance to degradation by nucleases. It can be used in research and drug development as a potential antiviral agent, due to its ability to inhibit viral replication by interfering with the viral RNA synthesis. Additionally, the compound may have potential applications in nucleoside analog therapy for the treatment of viral infections and certain types of cancer. Overall, (2'R)-2'-Deoxy-6-O-ethyl-2'-fluoro-2'-methylguanosine is a promising chemical with potential therapeutic benefits in the field of medicine.

Upstream product

• 64-17-5 ethanol 
• 1199809-26-1 (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate 
• 1294481-79-0 ((2R,3R,4R) 3-(4-chlorobenzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl-4-chlorobenzoate 
• 1294481-80-3 ((2R,3R,4R,5R)-3-((4-chlorobenzoyl)oxy)-4-fluoro-5-hydroxy-4-methyltetrahydrofuran-2-yl)methyl 4-chlorobenzoate 
• 1294481-81-4 (2R,3R,4R,5R)-5-bromo-2-(((4-chlorobenzoyl)oxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl 4-chlorobenzoate 
• 1294481-82-5 (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(((4-chlorobenzoyl)oxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl 4-chlorobenzoate 
• 141-52-6 sodium ethanolate 
• 10310-21-1 2-Amino-6-chloropurin 
• 874638-80-9 ((2R,3R,4R)-3-benzoyloxy-4-fluoro-4-methyl-5-oxo-tetrahydrofuran-2-yl)methyl benzoate 
• 1199809-24-9 (((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate) 
• 1199809-22-7 ((2R,3R,4R,5R)-3-(benzoyloxy)-4-fluoro-5-hydroxy-4-methyltetrahydrofuran-2-yl)methyl benzoate 

Downstream Products

• 1261254-07-2 C₂₅H₃₄FN₆O₈P 
• 1261254-05-0 C₂₃H₃₀FN₆O₈P 
• 1261253-86-4 C₂₄H₃₂FN₆O₈P 
• 1199809-32-9 PSI-938 
• 1604813-50-4 C₃₉H₄₉FN₁₂O₁₃P₂ 
• 1604813-47-9 C₄₁H₅₁FN₁₂O₁₃P₂ 
• 1604813-61-7 C₂₆H₂₇FN₅O₇P 
• 1199809-77-2 6-ethoxy-9-((2S,4aR,6R,7R,7aR)-7-fluoro-2-isopropoxy-7-methyl-2-oxo-tetrahydro-2λ(5)-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl)-9H-purin-2-ylamine 

Relevant articles and documents

The synthesis of hydroxyaminopurine nucleosied (by machine translation)

A compound or salt thereof having the following structure useful for the treatment of hepatitis C virus (HCV): wherein R 7 is C 1-6 alkyl or C 3-6 cycloalkyl and R 8 is -O(C 1-6 alkyl) or -O(C 3-6 cycloalkyl).

Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or i

2′-Deoxy-2′-α-fluoro-2′-β-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938

A series of novel 2′-deoxy-2′-α-fluoro-2′-β-C- methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs were synthesized and evaluated for their in vitro anti-HCV activity and safety. These prodrugs demonstrated a 10-100-fold greater potency than the parent nucleoside in a cell-based replicon assay due to higher cellular triphosphate levels. Our structure-activity relationship (SAR) studies provided compounds that gave high levels of active triphosphate in rat liver when administered orally to rats. These studies ultimately led to the selection of the clinical development candidate 24a (PSI-352938).